Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 12, 2019 08:05 ET | Source: NextCure

NextCure Reports Third Quarter 2019 Financial Results

BELTSVILLE, Md., Nov. 12, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
November 09, 2019 17:05 ET | Source: NextCure

NextCure Presents Updated Clinical Data from NC318 Phase 1/2 Clinical Trial at the 34th Annual Meeting of Society for Immunotherapy of Cancer (SITC) and Announces Initiation of Phase 2 Portion of the Trial

NC318 was well toleratedSingle agent activity observed in multiple tumor types, including a CR and a PR in NSCLCInitiated Phase 2 portion of the Phase 1/2 monotherapy trial and plans for a combo trial...
November 04, 2019 08:05 ET | Source: NextCure

NextCure to Host and Webcast Event at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

BELTSVILLE, Md., Nov. 04, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing next-generation immunomedicines for cancer and...
October 02, 2019 07:30 ET | Source: NextCure

NextCure Announces Promotion of Timothy Mayer, Ph.D., to Chief Operating Officer

BELTSVILLE, Md., Oct. 02, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
October 01, 2019 18:20 ET | Source: NextCure

NextCure to Present Clinical Data from NC318 Phase 1/2 Clinical Trial at 34th Annual Meeting of SITC

BELTSVILLE, Md., Oct. 01, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
September 03, 2019 16:05 ET | Source: NextCure

NextCure to Present at Morgan Stanley 17th Annual Global Healthcare Conference

BELTSVILLE, Md., Sept. 03, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
August 12, 2019 16:05 ET | Source: NextCure

NextCure Reports Second Quarter 2019 Financial Results

BELTSVILLE, Md., Aug. 12, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
June 10, 2019 16:05 ET | Source: NextCure

NextCure Reports First Quarter 2019 Financial Results

BELTSVILLE, Md., June 10, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
May 13, 2019 16:05 ET | Source: NextCure

NextCure Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

BELTSVILLE, Md., May 13, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
May 08, 2019 20:46 ET | Source: NextCure

NextCure Announces Pricing of Initial Public Offering of Common Stock

BELTSVILLE, Md., May 08, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...